Constipation Clinical Trial
Official title:
A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children
NCT number | NCT00319670 |
Other study ID # | 851-201 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | April 27, 2006 |
Last updated | February 6, 2013 |
Start date | March 2006 |
Verified date | February 2013 |
Source | Braintree Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.
Status | Completed |
Enrollment | 25 |
Est. completion date | |
Est. primary completion date | May 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 4 Years to 16 Years |
Eligibility |
Inclusion Criteria: 1. Male or female constipated outpatients between the ages of 4 and 16 2. Currently taking a dose of less than or equal to 17g of PEG 3350 powder that has been consistent for at least 4 weeks 3. Current treatment is considered successful - defined as greater than 2 bowel movements per week with no accidents 4. Are otherwise in good health, as judged by a physical examination 5. If female and of childbearing potential, patient must be using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study 6. In the investigator's judgment, patient or guardian is mentally competent to sign an instrument of informed consent Exclusion Criteria: 1. Patients with heme positive stool at baseline exam 2. Patients who are impacted at baseline exam 3. Patients that are not receiving PEG 3350 4. Patients on PEG 3350 that continue to have problems 5. Patients with known or suspected perforation or obstruction 6. Patients with a history of gastric retention, inflammatory bowel disease, bowel resection, or colostomy 7. Patients with a known history of organic cause for their constipation. 8. Patients currently using medications known to cause constipation. These include Opiates, antidepressants, SSRI's, antimotility agents and anticholinergics. 9. Patients who are breastfeeding, pregnant, or intend to become pregnant during the study 10. Female patients of childbearing potential who refuse a pregnancy test 11. Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedure 12. Patients with known allergy to PEG or PEG containing medications 13. Patients who, within the past 30 days have participated in an investigational clinical study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Braintree Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy will be measured by analysis of patient self-reported BM data. | |||
Primary | Adverse events will be monitored and analyzed for safety purposes. | |||
Secondary | Patient acceptance will be measured by analysis of subjective questionnaire data. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Recruiting |
NCT06292949 -
Clinical Study of Resistant Starch in Improving Constipation
|
N/A | |
Recruiting |
NCT04132661 -
MRI Assessment of Mode of Action of Bisacodyl, Single Dose
|
Phase 4 | |
Completed |
NCT02726295 -
The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study
|
Phase 4 | |
Terminated |
NCT02839889 -
Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)
|
Phase 4 | |
Recruiting |
NCT02255747 -
Anal Dilatation for Infants and Children With Constipation
|
N/A | |
Completed |
NCT02246647 -
Biomarkers for Intestinal Permeability in Patients With Constipation
|
||
Completed |
NCT01566409 -
Maintenance Treatment for Children With Constipation
|
N/A | |
Completed |
NCT02658201 -
Ultrafast MRI Imaging to Exclude Constipation
|
N/A | |
Completed |
NCT01710579 -
Normal Values in Ano-rectal 3D High Resolution Manometry
|
N/A | |
Completed |
NCT01695915 -
Diurnal Variation in Rectal Diameter
|
N/A | |
Completed |
NCT02863848 -
Effect of Inulin-type Fructans on Constipated Children.
|
N/A | |
Completed |
NCT01438567 -
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
|
Phase 3 | |
Completed |
NCT01474499 -
A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation
|
Phase 3 | |
Completed |
NCT01411501 -
Efficacy and Safety of Acupuncture for Functional Constipation
|
Phase 3 | |
Completed |
NCT01170039 -
The Effectiveness of Lubiprostone in Constipated Diabetics
|
Phase 4 | |
Completed |
NCT00931853 -
Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC).
|
Phase 3 | |
Active, not recruiting |
NCT02442115 -
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
|
||
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 | |
Completed |
NCT00994851 -
Evaluation of Cassia Fistula + Senna Alexandrina Miller in the Chronic Functional Constipation Treatment.
|
Phase 3 |